Skip to main content
. 2017 Mar 24;19(8):1047–1057. doi: 10.1093/neuonc/nox026

Table 1.

Pathological composition and characteristics of the analyzed mutational load patient cohort

Pathology All Patients GBM Gliosarcoma High Grade NOS Grade III Grade II Grade I Other
 WHO grade I + II + III + IV IV IV III/IV III II I ?
 Number of patients (%) 327 198 10 16 34 45 5 19
Parameters
Sex, no. (%)
 Male 179 (54.7) 110 (55.6) 6 (60.0) 8 (50.0) 19 (55.9) 23 (51.1) 3 (60.0) 10 (52.6)
 Female 148 (45.3) 88 (44.4) 4 (40.0) 8 (50.0) 15 (44.1) 22 (48.9) 2 (40.0) 9 (47.4)
 Age, mean y (range) 52.1 (0-85) 56.6 (4-85) 52.9 (35-63) 53.9 (28-81) 46.7 (21-73) 42.4 (18-78) 19.4 (0-56) 44.3 (15-74)
 <50 y 121 (37.0) 44 (22.2) 3 (30.0) 6 (37.5) 18 (52.9) 34 (75.6) 4 (80.0) 13 (68.4)
 ≥50 y 206 (63.0) 154 (77.8) 7 (70.0) 10 (62.5) 16 (47.1) 11 (24.4) 1 (20.0) 6 (31.6)
IDH1 mutation
 Wild type 248 182 10 12 10 16 5 13
 Mutated 79 16 0 4 24 29 0 6
Mutational load
<10 mutations/1.4 Mb (low) 279 171 8 13 25 41 5 16
11-20 mutations/1.4 Mb (moderate) 33 20 1 1 5 4 0 2
>20 mutations/1.4 Mb (high) 15 7 1 2 4 0 0 1
Mean TML ± SD 10.2 (±26.2) 9.8 (±27.7) 18.8 (±38.2) 11.1 (±17.5) 11.4 (±11.9) 6.7 (± 2.8) 4.8 (±2.7) 17.7 (±51.2)
PD-1/PD-L1 expression
PD-1 on TILs, no. / total no. (%)
 Positive 59/152 (38.8) 43/94 (45.7) 3/4 (75.0) 3/8 (37.5) 14/16 (87.5) 1/16 (6.2) 1/2 (50.0) 6/12 (50.0)
PD-L1 on tumor cells, no. / total no. (%)
 Positive 24/295 (8.1) 19/189 (10.1) 3/10 (30.0) 1/16 (6.2) 2/16 (12.5) 0/41 (0) 0/5 (0.0) 1/18 (5.5)
MMR protein expression
MLH1, no. / total no.
 Expression 33/35 28/30 0/1 2/2 0/1 3/3 1/1 3/3
MSH2, no. / total no.
 Expression 33/35 27/30 0/1 2/2 0/1 3/3 1/1 3/3
MSH6, no. / total no.
 Expression 31/34 26/30 0/1 2/2 0/1 2/2 1/1 3/3
PMS2, no. / total no.
 Expression 32/35 28/30 0/1 2/2 0/1 3/3 1/1 2/3